Eliasson E - Search Results

1

Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study.

Smith RL, Haslemo T, Andreassen OA, Eliasson E, Dahl ML, Spigset O, Molden E. Smith RL, et al. Among authors: eliasson e. CNS Drugs. 2017 Nov;31(11):991-997. doi: 10.1007/s40263-017-0469-1. CNS Drugs. 2017. PMID: 28948574

2

Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.

Mannheimer B, Haslemo T, Lindh JD, Eliasson E, Molden E. Mannheimer B, et al. Among authors: eliasson e. Ther Drug Monit. 2016 Feb;38(1):127-34. doi: 10.1097/FTD.0000000000000251. Ther Drug Monit. 2016. PMID: 26418700

3

Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.

Haslemo T, Eliasson E, Jukić MM, Ingelman-Sundberg M, Molden E. Haslemo T, et al. Among authors: eliasson e. Br J Clin Pharmacol. 2019 Jan;85(1):194-201. doi: 10.1111/bcp.13788. Epub 2018 Nov 11. Br J Clin Pharmacol. 2019. PMID: 30312494 Free PMC article.

4

UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in patients on maintenance treatment and in recombinant systems.

Haslemo T, Loryan I, Ueda N, Mannheimer B, Bertilsson L, Ingelman-Sundberg M, Molden E, Eliasson E. Haslemo T, et al. Among authors: eliasson e. Clin Pharmacol Ther. 2012 Aug;92(2):221-7. doi: 10.1038/clpt.2012.46. Epub 2012 Jun 20. Clin Pharmacol Ther. 2012. PMID: 22713701

5

Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles.

Thorén L, Lindh JD, Ackehed G, Kringen MK, Hall P, Bergh J, Molden E, Margolin S, Eliasson E. Thorén L, et al. Among authors: eliasson e. Br J Clin Pharmacol. 2021 Mar;87(3):1243-1252. doi: 10.1111/bcp.14500. Epub 2020 Aug 9. Br J Clin Pharmacol. 2021. PMID: 32713032 Free PMC article.

6

Therapeutic drug monitoring for tomorrow.

Eliasson E, Lindh JD, Malmström RE, Beck O, Dahl ML. Eliasson E, et al. Eur J Clin Pharmacol. 2013 May;69 Suppl 1:25-32. doi: 10.1007/s00228-013-1504-x. Epub 2013 May 3. Eur J Clin Pharmacol. 2013. PMID: 23640185 Review.

7

Tribute to Folke Sjöqvist, a Pioneer in Clinical Pharmacology.

Dahl ML, Bergman U, Bertilsson L, Eliasson E, Gustafsson LL, Panagiotidis G, Rane A. Dahl ML, et al. Among authors: eliasson e. Clin Pharmacol Ther. 2020 Dec;108(6):1127-1128. doi: 10.1002/cpt.1935. Epub 2020 Jul 8. Clin Pharmacol Ther. 2020. PMID: 32535883 No abstract available.

8

CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.

Margolin S, Lindh JD, Thorén L, Xie H, Koukel L, Dahl ML, Eliasson E. Margolin S, et al. Among authors: eliasson e. Pharmacogenomics. 2013 Apr;14(6):613-22. doi: 10.2217/pgs.13.47. Pharmacogenomics. 2013. PMID: 23570465

9

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype.

Yasar U, Forslund-Bergengren C, Tybring G, Dorado P, Llerena A, Sjöqvist F, Eliasson E, Dahl ML. Yasar U, et al. Among authors: eliasson e. Clin Pharmacol Ther. 2002 Jan;71(1):89-98. doi: 10.1067/mcp.2002.121216. Clin Pharmacol Ther. 2002. PMID: 11823761 Clinical Trial.

10

Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes.

Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML. Griskevicius L, et al. Among authors: eliasson e. Eur J Clin Pharmacol. 2003 Jun;59(2):103-9. doi: 10.1007/s00228-003-0590-6. Epub 2003 Apr 9. Eur J Clin Pharmacol. 2003. PMID: 12684728

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

138 results

Search Page